Cell-O-Matic, an exciting program about single cell genomics

Diagenode is proud to be part of this consortium that will aim at developing chip-based technologies that process DNA from individual cells, ready for Next-Generation high-throughput sequencing.

Cell-O-Matic (High Throughput Systematic Single-cell Genomics using Micro/Nano-Fluidic Chips for Extracting, Pre-analysis, Selecting and Preparing Sequence-ready DNA) consortium is made up of 13 partners-2 academic research groups, 9 SME's and 2 industries- from 8 different member states and funded by the seventh Framework FP-HEALTH.2011. This consortium will aim at developing methods that enable whole chromosome lengths of DNA to be contiguously mapped using nanofluidics.  The Cell-0-Matic project will also synergize efforts to develop chip-based technologies that process DNA from individual cells, ready for Next-Generation high-throughput sequencing. Hélène Pendeville Ph.D., R&D Manager Associate noted: "Improving the quality and throughput of sequencing technologies to access genome information at a single-cell level will have a profound impact on systems biology, including cancer. Diagenode is proud to be part of this exciting 4-year programme".

About Diagenode

Diagenode is a multinational life science company that develops and commercializes innovative instruments and reagents for epigenetic research. Major product lines include SX-8G IP-Star® Automation, Bioruptor® Sonication, epigenetic targeted ChIP-seq grade antibodies, kits for Chromatin Immunoprecipitation and DNA methylation studies. Founded in 2003 in Liège (Belgium), Diagenode has offices in Liège, Belgium and Denville, New Jersey.

Contact Information
Hélène Pendeville
R&D Manager Associate
Diagenode sa
Email Contact

March 13th 2012